Stem Cell Trial Yields Surprising Results

by Dan Roberts Advanced Cell Technology, Inc. (now owned by Astellas) has been conducting promising safety trials for stem cell treatment of macular degeneration, but a six-month follow up has yielded even better news than expected. ACT announced that Phase 1/2 clinical data treatment of Stargardt’s macular degeneration (SMD) and dry age-related macular degeneration (AMD). Surprising even [Read More]

Gene Profiling Technique Accelerates Stem Cell Therapies for Retinal Diseases

(Source: National Eye Institute, National Institutes of Health) Researchers at the National Institutes of Health have developed a technique that will streamline the production of stem-cell derived tissues. The technique will help the researchers in their efforts to use patients’ skin cells to create new retinal tissue, a therapy that has been recently applied to [Read More]

Squalamine Eye Drops Under Study for Wet AMD

(Updated 4/17/16) On June 24, 2014, Ohr Pharmaceutical, Inc. announced positive top-line interim results for its Phase 2 clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in multiple visual function including a gain in visual acuity of +10.4 letters with Squalamine eye [Read More]